Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings

Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense oligonucleotide targeting microRNA-22 (miR-22). The data was presented at the European Association for the Study of Diabetes (EASD) in Vienna, Austria, the Obesity Science & Innovation Meeting in Boston, MA, and the Obesity Drug Development Summit Europe in Barcelona, Spain. The study evaluated RES-010 in a well-defined, non-human primate (NHP) model for obesity as both a monotherapy and in combination with the GLP-1 receptor agonist (GLP-1 RA) semaglutide, while also assessing weight control after treatment discontinuation.

In this study, RES-010 demonstrated robust and durable weight reduction effects in obese NHPs maintained on a high-fat diet. After 10 weeks of treatment, RES-010 monotherapy achieved a 15% reduction in fat mass compared to semaglutide (16%), while also preserving lean mass (-1% with RES-010 versus -8% with semaglutide). In combination with semaglutide, RES-010 provided an additive benefit resulting in a 33% reduction of fat. Notably, after semaglutide interruption at week 10, the animals previously treated with the combination and still on RES-010 alone did not experience rebound weight gain despite a rapid increase in food intake. Four weeks after semaglutide discontinuation, animals that continued on RES-010 showed a further reduction of fat mass and a substantial recovery of lean mass. The stabilization of body weight observed with RES-010 treatment was sustained for at least 4 weeks in absence of any treatment.

“RES-010 delivers fat-selective weight loss, prevents rebound after GLP-1 RA discontinuation and shows durability beyond treatment, a truly unique feature in treating obesity,” said Riccardo Panella, CSO of Resalis Therapeutics. “Because primates closely model human biology, these results strengthen our confidence in RES-010’s profile as a first-in-class RNA therapy in obesity, with a clear differentiation from existing approaches. We are encouraged by these data and look forward to confirming its profile in our ongoing Phase 1 trial.”

“These results underscore RES-010’s potential to reshape obesity treatment by offering benefits not achieved with existing approaches,” said Alessandro Toniolo, CEO of Resalis Therapeutics. “Obesity is one of the fastest-growing health concerns worldwide, and there is a clear need for effective, durable, well-tolerated treatment options. We are excited to build on this momentum and are committed to our mission of transforming the standard of care in obesity.”

RES-010 is currently being evaluated in healthy lean and overweight to obese subjects. The ongoing Phase 1 trial (EUCT No.: 2024-514871-17-00) is designed to assess the safety, tolerability, and pharmacokinetic profile of RES-010 in the described population, with preliminary data expected in mid-2026.

About RES-010
RES-010 is designed to reprogram metabolic pathways, providing a potential disease-modifying therapeutic impact that could include high-quality, sustained weight loss. By specifically targeting miR-22, a master regulator of lipid biosynthesis, mitochondrial function, and adipose tissue transformation, RES-010 has the potential to go beyond conventional obesity treatments that focus solely on appetite reduction. This targeted approach has the potential to offer a more durable solution, addressing the complex biological underpinnings of obesity. The regulation of these pathways may result in a reduction of fat mass across various body parts, including visceral fat and hepatic stores. With its robust preclinical results, RES-010 has the potential to complement and enhance the efficacy of existing anti-obesity drugs, such as GLP-1 receptor agonists, and may extend their impact by providing a more comprehensive therapeutic solution.

About Resalis Therapeutics

Resalis Therapeutics is dedicated to developing RNA-based therapies that tackle the root causes of complex metabolic disorders. With its deep expertise in non-coding RNA and lipid metabolism, Resalis Therapeutics is advancing RES-010 as a safe, effective, and disease-modifying therapy, offering sustained weight loss and improved metabolic health. With strong preclinical data supporting its development, RES-010 is now in clinical trials, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.

For more information visit our website www.resalistherapeutics.com.

Contact:
Trophic Communications
Eva Mulder or Charlotte Spitz
+31 6 52 33 15 79
resalis@trophic.eu

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.